Diabytes
Lupin launches generic insomnia drug in US
Drug major Lupin has launched a generic insomnia drug, Zolpidem Sublingual tablets, in the US market with 180-days of marketing exclusivity.
Trending Photos
7- 6
- 12
- 6
New Delhi: Drug major Lupin has launched a generic insomnia drug, Zolpidem Sublingual tablets, in the US market with 180-days of marketing exclusivity.
Lupin Pharmaceuticals launched GAVIS Pharmaceuticals' Zolpidem Sublingual tablets after having received final approval from the United States Food and Drug Administration (FDA) as well as from the FTC with 180 days of exclusivity.
Reacting to the news, stock of Lupin was trading at Rs 1,465.30 on BSE, up 0.27 percent from the previous close.
Lupin had completed the acquisition of privately held US-based GAVIS Pharmaceuticals LLC and Novel Laboratories (GAVIS) in a USD 880 million deal earlier this month.
It had announced the acquisition on July 23, 2015.
GAVIS's product is the generic equivalent of Purdue Pharma LP's Intermezzo Sublingual tablets and is indicated for for the treatment of insomnia.
As per the IMS sales data, Intermezzo had sales of USD 9.46 million in the US market.
 "DNA: Analysis of BJP's first victory in Lok Sabha elections")
 "DNA: 'Mountain' of garbage in Delhi is giving competition to Qutub Minar")
 "DNA: Shocking report on plastic")
 "DNA: What is Bengal teacher recruitment scam?")
 "DNA: What did the mother of Love Jihad case accused Fayaz tell?")
 "DNA: Dangers of Using Counterfeit Airbags")
 "DNA: Modi Wave vs Heatwave in 2024 Lok Sabha Elections?")
 "DNA: Will Israel fight alone against Muslim countries?")
 "DNA: Is there plastic in your blood too?")
 "DNA: Threat of nuclear war?")
